Quietly crucial in prefilled syringes, Schott Pharma syriQ BioPure targets sensitive biologics
18.06.2026 - 10:00:50 | ad-hoc-news.de
Reviewed: ad hoc news Software & Services desk. Edited and checked on 2026-06-18, 09:57. Details in the imprint.
With syriQ BioPure, Schott Pharma sends a prefillable glass syringe into everyday hospital life that is built for extremely sensitive biologics and vaccines. Nurses see a clear, uniform syringe, while manufacturers get a tightly controlled primary packaging that aims to stay almost invisible to the drug.
Background on the Schott Pharma stock
Schott Pharma positions itself as a specialist for high-value drug containment and delivery systems, with prefillable syringes like syriQ BioPure playing a central role in its growth story.
What syriQ BioPure is built to do
syriQ BioPure is Schott Pharma’s premium line of prefillable glass syringes tailored for sophisticated biologics, including monoclonal antibodies and vaccines, where even minimal interaction with the container can destabilize the drug. The system is delivered ready-to-use in standardized nests and tubs to fit modern fill-and-finish lines.
According to Schott Pharma, the syringes rely on high-quality borosilicate glass, tight dimensional tolerances and carefully selected elastomer components to minimize protein aggregation and particle risk during storage. The company emphasizes low tungsten and low glue levels to avoid critical leachables that can trigger out-of-spec batches.
Design choices that matter for biologics
Visually, syriQ BioPure looks like a clean, clear syringe barrel with slender wall thickness and precisely formed cone and flange, but the details sit under the surface. Interior surfaces are optimized to reduce interaction, and coatings plus lubricants are tuned for smooth plunger movement without excess silicone oil.
Schott Pharma stresses that the syringes are designed to support a broad pH range and high-viscosity formulations that are common in biologics, aiming to keep plunger forces predictable for both manual injections and autoinjector use. The format portfolio spans common volumes, including 1 ml long, which is a workhorse size for subcutaneous biologic therapies.
Compatibility with devices and lines
For pharmaceutical customers, one key promise of syriQ BioPure is device compatibility. The syringes are engineered for use in safety devices and autoinjectors, where barrel diameter, flange geometry and break-loose forces must sit within tight windows to avoid misfiring or incomplete dosing.
Because they come in standard nests and tubs with ready-to-use sterilization, they can drop into existing high-speed filling lines with minimal changeover. That reduces glass-to-glass contact during processing and helps keep cosmetic defects low, which matters when regulators and quality units scrutinize every particle.
Where the limits still lie
Despite the high-end positioning, syriQ BioPure does not remove all development work for a biologic. Each formulation still needs compatibility testing to verify that proteins stay stable over the full shelf life in the chosen configuration, and that plunger movement remains consistent at cold-chain temperatures.
Hospitals and patients will rarely notice the brand name on the syringe, yet any deviation in component supply or quality could quickly surface as delivery issues. The concept is uncompromising: the primary packaging stays quietly out of the way, but any misstep would be immediately visible where it hurts most - at the point of care.
Context for investors
Schott Pharma positions syriQ BioPure as a strategic offering in the growth market for high-value biologics and vaccines, where demand for reliable, low-interaction primary packaging has risen alongside more complex molecules. The product family underpins long-term contracts with major pharmaceutical customers worldwide and strengthens recurring revenue streams.
Shares of Schott Pharma (DE000A3ENQ51) trade on Xetra in euros.
Key facts about syriQ BioPure
- Product: syriQ BioPure prefillable glass syringes
- Manufacturer: Schott Pharma AG & Co. KGaA
- Category: Software/Service/Subscription (packaging platform for pharma customers)
- Launch: Marketed as part of Schott Pharma’s biologics-focused syringe portfolio in recent years
- RRP / Price: Pricing is contract-based per thousand units and not publicly listed
- Availability: Sold B2B to pharmaceutical manufacturers globally for use in biologics and vaccine projects
- Target group: Pharma and biotech companies developing or commercializing injectable biologics and vaccines
- Highlight / USP: Prefillable glass syringe system optimized to minimize interaction with sensitive biologic drugs while supporting high-speed filling and autoinjector compatibility
This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.
